Rx-to-OTC switch meeting
This article was originally published in The Tan Sheet
Executive Summary
Consumer Healthcare Products Association planning July 29 meeting with FDA and industry representatives on OTC switches. The session is not intended to focus on a specific product category. However, ways around FDA's current position that hypercholesterolemia drugs are not appropriate switches is a likely topic for discussion
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning